Lipoprotein-bound LPS induces cytokine tolerance in hepatocytes

Abstract

Bacterial endotoxin (LPS) elicits dramatic responses in the host including elevated plasma lipid levels due to the increased synthesis and secretion of triglyceride (TG)-rich lipoproteins by the liver. We postulate that this cytokine-induced hyperlipoproteinemia, clinically termed the `lipemia of sepsis', represents an innate, non-adaptive host immune response to infection. Data in support of this hypothesis include the capacity of TG-rich lipoproteins (VLDL and chylomicrons, CM) to bind and neutralize LPS. Herein, we present evidence that CM-bound LPS attenuates the hepatocellular response to pro-inflammatory cytokines. Primary rodent hepatocytes pretreated with CM—LPS complexes for 2 h demonstrated a near 70% reduction in cytokine-induced NO production as compared to non-pretreated control cells (P ≥ 0.04). Whereas hepatocytes were maximally tolerant to cytokine stimulation 6 h after CM—LPS pretreatment, the cells spontaneously regained cytokine responsiveness within 40 h. The induction of cytokine tolerance in hepatocytes follows the internalization of CM—LPS complexes and is a process regulated by the LDL receptor. CM—LPS complexes failed to induce cytokine tolerance in hepatocytes wherein lipoprotein receptor activity was inhibited with high dose receptor associated protein (30 μg/ml). Similarly, CM-bound LPS did not induce tolerance in hepatocytes from ldlr ^—/— mice. Thus, the biochemical or genetic inhibition of LDL receptor activity effectively prevented the CM-mediated induction of the cytokine tolerant phenotype. In conclusion, the lipemia of sepsis likely represents a mechanism by which the host combats sporadic, non-life-threatening episodes of endotoxemia. Also, it may indicate a negative regulatory mechanism for the hepatic response to sepsis, serving to effectively down-regulate the acute phase response. A better understanding of how TG-rich lipoproteins modulate the host response to LPS could yield novel biological insights with important clinical implications, including the development of lipid-based therapies for bacterial infections.

References

Banerjee S. , Bhaduri J. Serum protein-bound carbohydrates and lipids in cholera. Proc Exp Biol Med 1959; 101: 340—341.

Gallin JI , Kaye D. , O'Leary WM. Serum lipids in infection. N Engl J Med 1969; 281: 1081—1086.

Ulevitch RJ , Johnston AR , Weinstein DB New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest 1979; 64: 1516—1524.

Harris HW , Grunfeld C. , Feingold KR , Rapp JH Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990; 86: 696—702.

Harris HW , Rockey DC , Young DM , Welch WJ Diet-induced protection against lipopolysaccharide includes increased hepatic NO production. J Surg Res 1999; 82: 339—345.

Read TE , Grunfeld C. , Kumwenda Z. et al. Triglyceride-rich lipoproteins improve survival when given after endotoxin in rats. Surgery 1995; 117: 62—67.

Rensen PC , Oosten M. , Bilt E. , Eck M. , Kuiper J. , Berkel TJ Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats in vivo. J Clin Invest 1997; 99: 2438—2445.

Harris HW , Rockey DC , Chau P. Chylomicrons alter the hepatic distribution and cellular response to endotoxin in rats. Hepatology 1998; 27: 1341—1348.

Van Oosten M , Rensen PC , Van Amersfoort ES et al. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat Gram-negative sepsis. J Biol Chem 2001; 276: 8820—8824.

10.

de Bont N. , Netea MG , Demacker PN et al. Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. J Lipid Res 1999; 40: 680—685.

11.

Kumwenda Z. , Welch W. , Harris H. Chylomicron-bound endotoxin inhibits hepatocellular nitric oxide production by inhibiting nuclear factor-κB activation in rats. Surg Forum 1998; 49: 8—9.

12.

Kumwenda ZL , Wong CB , Johnson JA , Gosnell JE , Welch WJ , Harris HW Chylomicron-bound endotoxin selectively inhibits NF-kappaB activation in rat hepatocytes. Shock 2002; 18: 182—188.

13.

Harris HW , Gosnell JE , Kumwenda ZL The lipemia of sepsis: triglyceride-rich lipoproteins as agents of innate immunity. J Endotoxin Res 2000; 6: 421—430.

14.

Chappell DA , Medh JD Receptor-mediated mechanisms of lipoprotein remnant catabolism. Prog Lipid Res 1998; 37: 393—422.

15.

Redgrave TG , Maranhao RC Metabolism of protein-free lipid emulsion models of chylomicrons in rats. Biochim Biophys Acta 1985; 835: 104—112.

16.

Zeng BJ , Mortimer BC , Martins IJ , Seydel U. , Redgrave TG Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J Lipid Res 1998; 39: 845—860.

17.

Kasravi F. , Welch WJ , Peters-Lideu C. , Weisgraber K. , Harris HW Induction of cytokine tolerance in rodent hepatocytes by chylomicron-bound LPS is LDL receptor dependent. Shock 2003; In Press

18.

Read TE , Harris HW , Grunfeld C. , Feingold KR , Kane JP , Rapp JH The protective effect of serum lipoproteins against bacterial lipopolysaccharide . Eur Heart J 1993; 14 (Suppl K): 125—129.

19.

Roselaar SE , Daugherty A. Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. J Lipid Res 1998; 39: 1740—1743.

20.

de Bont N. , Netea MG , Demacker PN , Kullberg BJ , van der Meer JW , Stalenhoef AF Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. Eur J Clin Invest 2000; 30: 818—822.

21.

Mahley RW , Rall Jr SC Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1: 507—537.